InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by ROTHBLATT MARTINE A, Founder, Chairperson, and Chief Executive Officer. Insider active across 1 companies, notably UNITED THERAPEUTICS Corp. In total, 34 filings have been recorded. The latest transaction was disclosed on 14 May 2026 — Levée d'options. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations34 total
€1m9,500 shares@ €125.21780.0049% mcap23.8% of flow
Common Stock
SEC:0001106578-26-000054·
€1m9,500 shares@ €125.21780.0049% mcap11.2% of flow
Common Stock
SEC:0001106578-26-000054:0·
US$1m9,500 shares@ US$124.6410.0049% mcap23.7% of flow
Common Stock
SEC:0001106578-26-000053·
€1m9,500 shares@ €124.6410.0049% mcap11.2% of flow
Common Stock
SEC:0001106578-26-000053:0·
US$1m9,500 shares@ US$124.43510.0049% mcap23.6% of flow
Common Stock
SEC:0001106578-26-000052·
€1m9,500 shares@ €124.43510.0049% mcap11.1% of flow
Common Stock
SEC:0001106578-26-000052:0·
€152,9543,000 shares@ €50.98480.0006% mcap1.4% of flow
Common Stock
SEC:0001415889-22-006115:0·
€149,3163,000 shares@ €49.77190.0006% mcap1.4% of flow
Common Stock
SEC:0001415889-22-005969:0·
€149,9633,000 shares@ €49.98780.0006% mcap1.4% of flow
Common Stock
SEC:0001415889-22-005712:0·
€150,0273,000 shares@ €50.00910.0006% mcap1.4% of flow
Common Stock
SEC:0001415889-22-005659:0·
€145,5093,082 shares@ €47.21260.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-031986·
€145,5093,082 shares@ €47.21260.0006% mcap1.4% of flow
Common Stock
SEC:0001127602-21-031986:0·
€145,3873,082 shares@ €47.17310.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-031936·
€145,3873,082 shares@ €47.17310.0006% mcap1.4% of flow
Common Stock
SEC:0001127602-21-031936:0·
€145,8603,082 shares@ €47.32640.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-031804·
€145,8603,082 shares@ €47.32640.0006% mcap1.4% of flow
Common Stock
SEC:0001127602-21-031804:0·
€146,4313,082 shares@ €47.51170.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-031688·
€146,4313,082 shares@ €47.51170.0006% mcap1.4% of flow
Common Stock
SEC:0001127602-21-031688:0·
€146,4613,083 shares@ €47.50590.0006% mcap2.9% of flow
Common Stock
SEC:0001104659-21-144459·
€146,4613,083 shares@ €47.50590.0006% mcap1.4% of flow
Common Stock
SEC:0001104659-21-144459:0·
€146,0603,083 shares@ €47.37610.0006% mcap2.9% of flow
Common Stock
SEC:0001104659-21-143603·
€146,0603,083 shares@ €47.37610.0006% mcap1.4% of flow
Common Stock
SEC:0001104659-21-143603:0·
€145,4743,083 shares@ €47.18590.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-029480·
€145,4743,083 shares@ €47.18590.0006% mcap1.4% of flow
Common Stock
SEC:0001127602-21-029480:0·
€143,9423,083 shares@ €46.68910.0006% mcap2.9% of flow
Common Stock
SEC:0001127602-21-029127·
25 of 34 declarations
About ROTHBLATT MARTINE A
Martine Rothblatt is the founder of United Therapeutics Corp., which she established in 1996 and has led ever since as Chairperson and Chief Executive Officer. Her most notable current role is therefore the company’s top executive and board leader, overseeing strategy, innovation, and long-term direction at a Nasdaq-listed U.S. biotechnology company. Under her leadership, United Therapeutics has grown around a clear mission: addressing unmet medical needs in rare diseases and pursuing solutions to expand the supply of transplantable organs. Rothblatt’s career path is distinctive for combining law, management, medical ethics, and technology entrepreneurship. She holds a bachelor’s degree in communications, an MBA, and a JD from UCLA, as well as a PhD in medical ethics from the University of London. Before and alongside United Therapeutics, she also founded SiriusXM, demonstrating an ability to build companies in complex, highly regulated industries. At United Therapeutics, she has helped shape a corporate culture focused on research, public health, and breakthrough innovation. She played a central role in positioning the company as a public benefit corporation, aligning governance with broader objectives related to patients, employees, communities, and social impact. That move reinforced the company’s identity as an organization seeking both financial performance and a long-term medical mission. Her notable achievements include advancing a strategy centered on rare lung diseases, innovative therapies, and technologies intended to address the shortage of donor organs. Rothblatt is also known for her work in bioethics, future medicine, and the societal implications of emerging technologies. She is an inventor or co-inventor on multiple U.S. patents, which further reflects her direct involvement in innovation. Overall, Martine Rothblatt is a highly influential corporate leader whose profile combines strategic vision, entrepreneurial execution, and sustained commitment to healthcare transformation.
